Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients

NCT05857085 is registered in ClinicalTrials.gov with General and Teaching Hospital Celje as lead sponsor.

NCT NCT05857085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients
Lead sponsor
General and Teaching Hospital Celje
Phase
Phase 4
Overall status
Completed
Start date
December 15, 2021
Completion date
April 20, 2023
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial stiffness, biomarkers, diabetes mellitus, type 1, endothelial dysfunction, endothelial progenitor cells, fmd, fpf, glucose excursions, incretins, sglt 2 inhibitors